Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

AXL targeting overcomes human lung cancer cell resistance to NK and CTL-mediated cytotoxicity.

Terry S, Abdou A, Engelsen AST, Buart S, Dessen P, Corgnac S, Collares D, Meurice G, Gausdal G, Baud V, Saintigny P, Lorens JB, Thiery JP, Mami-Chouaib F, Chouaib S.

Cancer Immunol Res. 2019 Sep 5. pii: canimm.0903.2019. doi: 10.1158/2326-6066.CIR-18-0903. [Epub ahead of print]

PMID:
31488404
2.

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2019 Jul;121(3):283. doi: 10.1038/s41416-019-0512-8.

3.

Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.

Bonnin M, Fares N, Testoni B, Estornes Y, Weber K, Vanbervliet B, Lefrançois L, Garcia A, Kfoury A, Pez F, Coste I, Saintigny P, Viari A, Lang K, Guey B, Hervieu V, Bancel B, Bartoch B, Durantel D, Renno T, Merle P, Lebecque S.

J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30351-4. doi: 10.1016/j.jhep.2019.05.031. [Epub ahead of print]

PMID:
31220470
4.

Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations.

Jagadeeshan S, Prasad M, Ortiz-Cuaran S, Gregoire V, Saintigny P, Elkabets M.

Trends Cancer. 2019 Jun;5(6):365-390. doi: 10.1016/j.trecan.2019.04.004. Epub 2019 May 28. Review.

PMID:
31208698
5.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R.

Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.

PMID:
31011205
6.

mTOR Signalling in Head and Neck Cancer: Heads Up.

Tan FH, Bai Y, Saintigny P, Darido C.

Cells. 2019 Apr 9;8(4). pii: E333. doi: 10.3390/cells8040333. Review.

7.

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again.

Hofman P, Ayache N, Barbry P, Barlaud M, Bel A, Blancou P, Checler F, Chevillard S, Cristofari G, Demory M, Esnault V, Falandry C, Gilson E, Guérin O, Glaichenhaus N, Guigay J, Ilié M, Mari B, Marquette CH, Paquis-Flucklinger V, Prate F, Saintigny P, Seitz-Polsky B, Skhiri T, Van Obberghen-Schilling E, Van Obberghen E, Yvan-Charvet L.

Cancers (Basel). 2019 Feb 21;11(2). pii: E250. doi: 10.3390/cancers11020250.

8.

Oral cancer prevention worldwide: Challenges and perspectives.

Foy JP, Bertolus C, Saintigny P.

Oral Oncol. 2019 Jan;88:91-94. doi: 10.1016/j.oraloncology.2018.11.008. Epub 2018 Nov 22. No abstract available.

PMID:
30616804
9.

Immunological and classical subtypes of oral premalignant lesions.

Foy JP, Bertolus C, Ortiz-Cuaran S, Albaret MA, Williams WN, Lang W, Destandau S, Souza G, Sohier E, Kielbassa J, Thomas E, Deneuve S, Goudot P, Puisieux A, Viari A, Mao L, Caux C, Lippman SM, Saintigny P.

Oncoimmunology. 2018 Sep 21;7(12):e1496880. doi: 10.1080/2162402X.2018.1496880. eCollection 2018.

10.

Externalized Keratin 8: A Target at the Interface of Microenvironment and Intracellular Signaling in Colorectal Cancer Cells.

Albaret MA, Vermot-Desroches C, Paré A, Roca-Martinez JX, Malet L, Esseily J, Gerossier L, Brière J, Pion N, Marcel V, Catez F, De Souza G, Vuillermoz B, Doerflinger F, Lavocat E, Subiger O, Rousset C, Bresson C, Mandon E, Jawhari A, Falson P, Jasmin M, Coute Y, Mertani HC, Saintigny P, Diaz JJ.

Cancers (Basel). 2018 Nov 16;10(11). pii: E452. doi: 10.3390/cancers10110452.

11.

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2018 Oct;119(8):950-960. doi: 10.1038/s41416-018-0220-9. Epub 2018 Oct 15. Erratum in: Br J Cancer. 2019 Jul;121(3):283.

12.

Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK.

Cancer. 2018 Sep 15;124(18):3693-3705. doi: 10.1002/cncr.31600. Epub 2018 Oct 5.

PMID:
30289966
13.

[Smoking and alcohol cessation programs in patients with head and neck cancer].

Hamant C, Deneuve S, Albaret MA, Zrounba P, Breton P, Céruse P, Gleizal A, Alix T, Bettega G, Chauvin F, Saintigny P, Régnier Denois V.

Bull Cancer. 2018 Nov;105(11):1012-1019. doi: 10.1016/j.bulcan.2018.07.006. Epub 2018 Sep 7. French.

PMID:
30201374
14.

Hey1- and p53-dependent TrkC proapoptotic activity controls neuroblastoma growth.

Ménard M, Costechareyre C, Ichim G, Blachier J, Neves D, Jarrosson-Wuilleme L, Depping R, Koster J, Saintigny P, Mehlen P, Tauszig-Delamasure S.

PLoS Biol. 2018 May 11;16(5):e2002912. doi: 10.1371/journal.pbio.2002912. eCollection 2018 May.

15.

Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.

Saintigny P, William WN Jr, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM.

J Natl Cancer Inst. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx186.

16.

Anti-Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?

Marchand L, Thivolet A, Saintigny P, Fabien N, Vouillarmet J, Thivolet C.

Diabetes Care. 2018 Mar;41(3):638-639. doi: 10.2337/dc17-2243. No abstract available.

PMID:
29463667
17.

The SCN9A channel and plasma membrane depolarization promote cellular senescence through Rb pathway.

Warnier M, Flaman JM, Chouabe C, Wiel C, Gras B, Griveau A, Blanc E, Foy JP, Mathot P, Saintigny P, Van Coppenolle F, Vindrieux D, Martin N, Bernard D.

Aging Cell. 2018 Jun;17(3):e12736. doi: 10.1111/acel.12736. Epub 2018 Feb 15.

18.

Bibliometric analysis of a century of research on oral erythroplakia and leukoplakia.

Foy JP, Bertolus C, Goudot P, Deneuve S, Blanc E, Lasset C, Pérol D, Saintigny P.

J Oral Pathol Med. 2018 Apr;47(4):388-395. doi: 10.1111/jop.12683. Epub 2018 Feb 13.

PMID:
29344996
19.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response.

Marchand L, Paulus V, Fabien N, Pérol M, Thivolet C, Vouillarmet J, Saintigny P.

J Thorac Oncol. 2017 Nov;12(11):e182-e184. doi: 10.1016/j.jtho.2017.07.021. No abstract available.

20.

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.

Dantas-Barbosa C, Lesluyes T, Loarer FL, Chibon F, Treilleux I, Coindre JM, Meeus P, Brahmi M, Bally O, Ray-Coquard I, Sunyach MP, Cesne AL, Mir O, Bonvalot S, Toulmonde M, Italiano A, Saintigny P, Jean-Denis M, Ducimetiere F, Ranchere D, El Sayadi H, Alberti L, Blay JY.

Br J Cancer. 2017 Dec 5;117(12):1787-1797. doi: 10.1038/bjc.2017.354. Epub 2017 Oct 12.

21.

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F.

Oncoimmunology. 2017 Jun 16;6(9):e1339856. doi: 10.1080/2162402X.2017.1339856. eCollection 2017.

22.

A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.

Foy JP, Bazire L, Ortiz-Cuaran S, Deneuve S, Kielbassa J, Thomas E, Viari A, Puisieux A, Goudot P, Bertolus C, Foray N, Kirova Y, Verrelle P, Saintigny P.

BMC Med. 2017 Sep 1;15(1):165. doi: 10.1186/s12916-017-0929-y.

23.

Non-canonical NOTCH3 signalling limits tumour angiogenesis.

Lin S, Negulescu A, Bulusu S, Gibert B, Delcros JG, Ducarouge B, Rama N, Gadot N, Treilleux I, Saintigny P, Meurette O, Mehlen P.

Nat Commun. 2017 Jul 18;8:16074. doi: 10.1038/ncomms16074.

24.

New insights into the role of EMT in tumor immune escape.

Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S.

Mol Oncol. 2017 Jul;11(7):824-846. doi: 10.1002/1878-0261.12093. Epub 2017 Jun 27. Review.

25.

The promising impact of molecular profiling on treatment strategies in oral cancers.

Foy JP, Saintigny P, Goudot P, Schouman T, Bertolus C.

J Stomatol Oral Maxillofac Surg. 2017 Sep;118(4):242-247. doi: 10.1016/j.jormas.2017.05.004. Epub 2017 May 30. Review.

PMID:
28576460
26.

The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.

Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P.

Ann Oncol. 2017 Aug 1;28(8):1934-1941. doi: 10.1093/annonc/mdx210.

27.

A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability.

Morel AP, Ginestier C, Pommier RM, Cabaud O, Ruiz E, Wicinski J, Devouassoux-Shisheboran M, Combaret V, Finetti P, Chassot C, Pinatel C, Fauvet F, Saintigny P, Thomas E, Moyret-Lalle C, Lachuer J, Despras E, Jauffret JL, Bertucci F, Guitton J, Wierinckx A, Wang Q, Radosevic-Robin N, Penault-Llorca F, Cox DG, Hollande F, Ansieau S, Caramel J, Birnbaum D, Vigneron AM, Tissier A, Charafe-Jauffret E, Puisieux A.

Nat Med. 2017 May;23(5):568-578. doi: 10.1038/nm.4323. Epub 2017 Apr 10.

PMID:
28394329
28.

Chemotherapy for recurrent/metastatic head and neck cancers.

Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J.

Anticancer Drugs. 2017 Apr;28(4):357-361. doi: 10.1097/CAD.0000000000000473. Review.

PMID:
28166090
29.

Chemotherapy for localized head and neck squamous cell cancers.

Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J.

Anticancer Drugs. 2017 Apr;28(4):362-368. doi: 10.1097/CAD.0000000000000480. Review.

PMID:
28134662
30.

Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.

Marcel V, Catez F, Berger CM, Perrial E, Plesa A, Thomas X, Mattei E, Hayette S, Saintigny P, Bouvet P, Diaz JJ, Dumontet C.

PLoS One. 2017 Jan 19;12(1):e0170160. doi: 10.1371/journal.pone.0170160. eCollection 2017.

31.

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers.

Ferrari A, Sertier AS, Vincent-Salomon A, Pivot X, Pauporté I, Saintigny P, Birnbaum D, Viari A.

Mol Cell Oncol. 2016 Sep 12;3(6):e1232186. doi: 10.1080/23723556.2016.1232186. eCollection 2016.

32.

[Contribution and challenges of Big Data in oncology].

Saintigny P, Foy JP, Ferrari A, Cassier P, Viari A, Puisieux A.

Bull Cancer. 2017 Mar;104(3):281-287. doi: 10.1016/j.bulcan.2016.10.020. Epub 2016 Nov 25. Review. French.

PMID:
27894504
33.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

34.

MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.

Bonnin N, Armandy E, Carras J, Ferrandon S, Battiston-Montagne P, Aubry M, Guihard S, Meyronet D, Foy JP, Saintigny P, Ledrappier S, Jung A, Rimokh R, Rodriguez-Lafrasse C, Poncet D.

Oncotarget. 2016 Jul 12;7(28):44023-44038. doi: 10.18632/oncotarget.9829.

35.

The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer.

Foy JP, Tortereau A, Caulin C, Le Texier V, Lavergne E, Thomas E, Chabaud S, Perol D, Lachuer J, Lang W, Hong WK, Goudot P, Lippman SM, Bertolus C, Saintigny P.

Oncotarget. 2016 Jun 14;7(24):35932-35945. doi: 10.18632/oncotarget.8321.

36.

Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM.

JAMA Oncol. 2016 Feb;2(2):209-16. doi: 10.1001/jamaoncol.2015.4364.

37.

New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development.

Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN Jr, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P.

Cancer Prev Res (Phila). 2015 Nov;8(11):1027-35. doi: 10.1158/1940-6207.CAPR-14-0179. Epub 2015 Sep 4.

38.

Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.

Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV.

BMC Genomics. 2014 Dec 8;15:1079. doi: 10.1186/1471-2164-15-1079.

39.

Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.

Malouf GG, Job S, Paradis V, Fabre M, Brugières L, Saintigny P, Vescovo L, Belghiti J, Branchereau S, Faivre S, de Reyniès A, Raymond E.

Hepatology. 2014 Jun;59(6):2228-37. doi: 10.1002/hep.27018. Epub 2014 Apr 30.

PMID:
24443104
40.

Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.

Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM.

Clin Cancer Res. 2013 Dec 15;19(24):6967-75. doi: 10.1158/1078-0432.CCR-12-1818. Epub 2013 Oct 28.

41.

Proliferative verrucous leukoplakia: recognition and differentiation from conventional leukoplakia and mimics.

Gillenwater AM, Vigneswaran N, Fatani H, Saintigny P, El-Naggar AK.

Head Neck. 2014 Nov;36(11):1662-8. doi: 10.1002/hed.23505. Epub 2014 Aug 28. Review.

PMID:
24115154
42.

Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity!

Gillenwater AM, Vigneswaran N, Fatani H, Saintigny P, El-Naggar AK.

Adv Anat Pathol. 2013 Nov;20(6):416-23. doi: 10.1097/PAP.0b013e3182a92df1. Review.

PMID:
24113312
43.

Oral premalignancy: the roles of early detection and chemoprevention.

Foy JP, Bertolus C, William WN Jr, Saintigny P.

Otolaryngol Clin North Am. 2013 Aug;46(4):579-97. doi: 10.1016/j.otc.2013.04.010. Epub 2013 May 25. Review.

44.

Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.

Lévy P, Gligorov J, Antoine M, Rezai K, Lévy E, Selle F, Saintigny P, Lokiec F, Avenin D, Beerblock K, Lotz JP, Bernaudin JF, Fajac A.

Breast Cancer Res Treat. 2013 Jun;139(2):421-8. doi: 10.1007/s10549-013-2545-7. Epub 2013 May 11.

PMID:
23666532
45.

Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.

Zhang L, Mitani Y, Caulin C, Rao PH, Kies MS, Saintigny P, Zhang N, Weber RS, Lippman SM, El-Naggar AK.

Am J Pathol. 2013 Jun;182(6):2048-57. doi: 10.1016/j.ajpath.2013.02.020. Epub 2013 Apr 10.

46.

EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.

Cao W, Ribeiro Rde O, Liu D, Saintigny P, Xia R, Xue Y, Lin R, Mao L, Ren H.

PLoS One. 2012;7(12):e52984. doi: 10.1371/journal.pone.0052984. Epub 2012 Dec 31.

47.

CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS.

Cancer Res. 2013 Jan 15;73(2):571-82. doi: 10.1158/0008-5472.CAN-12-0263. Epub 2012 Nov 30.

48.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

49.

Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.

Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II.

Cancer Prev Res (Phila). 2013 Jan;6(1):8-17. doi: 10.1158/1940-6207.CAPR-12-0290. Epub 2012 Oct 19.

50.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV.

Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6.

Supplemental Content

Loading ...
Support Center